Is SAB Biotherapeutics, Inc. overvalued or undervalued?

As of 9 May 2025, the valuation grade for SAB Biotherapeutics, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently assessed as overvalued, given its negative financial ratios and lack of profitability. Key ratios include a Price to Book Value of 0.79, an EV to EBIT of -0.12, and an EV to EBITDA of -0.13, all of which reflect the company's struggles in generating positive earnings.
In comparison to its peers, SAB Biotherapeutics shows a less favorable position, with companies like Quince Therapeutics, Inc. and VistaGen Therapeutics, Inc. also classified as does not qualify, but with more negative valuations of -1.6083 and -1.4589 respectively. The company's performance has been particularly poor, with a year-to-date return of -53.61%, significantly underperforming the S&P 500, which has returned 2.44% in the same period. This underperformance, combined with the negative financial metrics, reinforces the conclusion that SAB Biotherapeutics is overvalued in the current market.